p16INK4A, CDC6, and MCM5: Predictive biomarkers in cervical preinvasive neoplasia and cervical cancer

Journal of Clinical Pathology

Volumn 58, Issue 5, 2005, Pages 525-534

  Murphy, N ^b   Ring, M ^a   Heffron, C C B B ^b   King, B ^a   Killalea, A G ^a   Hughes, C ^a   Martin, C M ^b   McGuinness, E ^a   Sheils, O ^b   O'Leary, J J ^a,b  

^a Pathology Research Laboratory   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL CYCLE PROTEIN 6; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 5; MONOCLONAL ANTIBODY; PROTEIN P16INK4A; TUMOR MARKER; UNCLASSIFIED DRUG; CDC6 PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; MCM5 PROTEIN, S POMBE; NUCLEAR PROTEIN; SCHIZOSACCHAROMYCES POMBE PROTEIN; TUMOR PROTEIN;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INFECTION RISK; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STAINING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VIRUS DETECTION; WART VIRUS; WESTERN BLOTTING; CHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; PAPILLOMA VIRUS; RISK FACTOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; VIRUS INFECTION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SCHIZOSACCHAROMYCES POMBE PROTEINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 20844443130     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.018895     Document Type: Article

References (56)

1. Fausch SC, Da Silva DM, Eiben GL, et al. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci 2003;8:81-91.
2. Frazer I. Vaccines for papillomavirus infection. Virus Res 2002;89:271-4.
3. Kirwan JM, Herrington CS. Human papillomavirus and cervical cancer: where are we now? Br J Obstet Gynaenecol 2001;108:1204-13.
4. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
5. Bohmer G, Van den Brule AJ, Brummer O, et al. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 2003;189:118-20.
6. Giannoudis A, Herrington SC. Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 2001;193:295-302.
7. INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep™ smears. J Clin Pathol 2003;56:53-63.
8. Klaes R, Benner A, Friedrich T, et al. p16INK4A immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-99.
9. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16 as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
10. Bonds L, Baker P, Gup C, et al. Immunohistochemical localization of CDC6 in squamous and glandular neoplasia of the uterine cervix. Arch Pathol Lab Med 2002;126:1162-8.
11. Fujita M, Yamada C, Goto H. Cell cycle regulation of human Cdc 6 protein. J Biol Chem 1999;274:25927-32.
12. Williams GH, Coleman N. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-32.
13. Williams GH, Romanowski P, Morris L, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci U S A 1998;99:14932-7.
14. Yoshinouchi M, Hongo A, Takamoto N, et al. Alteration of the CDKN2/P16 gene is not required for HPV-positive uterine cervical cell lines. Int J Oncol 2000;16:537-41.
15. Li Y, Nichols MA, Shay JW, et al. Transcriptional repression of the D-type cyclin dependent kinase inhibitor p16 by retinoblastoma susceptibility gene product pRb. Cancer Res 1994;54:6078-82.
16. INK4A. Cancer Res 1994;54:5816-20.
17. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996;65:442-5.
18. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with E2F-mediated induction of cyclin-kinase activity. Proc Natl Acad Sci USA 2001;93:4350-4.
19. Bibbo M, DeCecco J, Kovatich AJ. p16INK4a as an adjunct test in liquid based cytology. Anal Quant Cytol Histol 2003;25:8-11.
20. Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol 2003;22:378-85.
21. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis or adenocarcinoma of the cervix uteri and its precursors: an immunohistological study with immunocytochemical correlations. Am J Surg Pathol 2003;27:187-93.
22. Pientang C, Ekalaksananan T, Swadpanich U, et al. Immunocytochemical detection of p16INK4a protein in scraped cervical cells. Acta Cytol 2003;47:616-23.
23. Saqi A, Pasha TI, McGrath CM, et al. Overexpression of p16INK4A in liquid-based specimens (SurePath) as a marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002;27:365-70.
24. Diffley JF, Labib K. The chromosome replication cycle. J Cell Sci 2002;115:869-72.
25. Takisawa H, Mimura S, Kubota Y. Eukaryotic DNA replication: from prereplication complex to initiation complex. Curr Opin Cell Biol 2000;12:690-6.
26. Shin JH, Grabowski B, Kasiviswanathan R, et al. Regulation of minichromosome maintenance helicase activity by Cdc6. J Biol Chem 2003;278:38059-67.
27. Cook JG, Park CH, Burke TW, et al. Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A 2002;99:1347-52.
28. Ishimi Y, Okayasu I, Kato C, et al. Enhanced expression of MCM proteins in cells derived from the uterine cervix. Eur J Biochem 2003;260:1089-101.
29. Davidson EJ, Morris LS, Scott IS, et al. Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer 2003;88:257-62.
30. Alison MR, Hunt T, Forbes SJ. Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Cancer 2002;50:291-2.
31. Davies RJ, Freeman A, Morris LS, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002;359:1917-19.
32. Going JJ, Keith WN, Neilson L, et al. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Cut 2002;50:373-7.
33. Stoeber K, Swinn R, Prevost AT, et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 2002;94:1071-9.
34. Ohta S, Koide M, Tokuyama T, et al. Cdc6 expression as a marker of proliferative activity in brain tumors. Oncol Rep 2001;5:1063-6.
35. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-32.
36. Sano T, Oyama T, Kashiwabara K, et al. Overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int 1998;48:580-8.
37. Milde-Langosch K, Hagen M, Bamberger AM, et al. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439:55-61.
38. Henshall SM, Quinn DI, Lee CS, et al. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 2001;7:544-50.
39. Ferreux E, Lont AP, Horenblas S, et al. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 2003;201:109-18.
40. Tripathi Bhar A, Banerjee S, Roy A, et al. Alterations of the P16 gene in uterine cervical carcinoma from Indian patients. Int J Gynecol Cancer 2003;13:472-9.
41. Dong SM, Kim HS, Rha SH, et al. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001;7:1982-6.
42. Nakashima R, Fujita M, Enomoto T, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999;80:458-67.
43. Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 1999;96:12754-9.
44. Myohanen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res 1998;58:591-3.
45. Wong YF, Chung TK, Cheung TH, et al. Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett 1999;136:231-5.
46. Reithdorf L, Reithdorf S, Lee KR, et al. Human papillomavirus expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002;33:899-904.
47. Cameron RI, Maxwell P, Jenkins D, et al. Immunohistochemical staining with MIB1, bcl2, and p16 assist in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002;41:313-21.
48. Ohtani K, Iwanaga R, Nakamura M, et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by transcription factor E2F. Oncogene 1999;14:2299-309.
49. Petersen B, Lukas J, Sorensen C, et al. Phosphorylation of mammalian Cdc6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J 1999;18:396-410.
50. Saha P, Chen J, Lawlis SJ, et al. Human CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase. Mol Cell Biol 1998;18:2758-67.
51. Biermann E, Baack M, Kreitz S, et al. Synthesis and turnover of the replicative CDC6 protein during the HeLa cell cycle. Eur J Biochem 2002;269:1040-6.
52. Petersen B, Wagener C, Marinoni F, et al. Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes Dev 2000;14:2330-43.
53. Clay-Farrace L, Pelizon C, Santamaria D, et al. Human replication protein Cdc6 prevents mitosis through a mechanism that implicates Chk1. EMBO J 2003;22:704-12.
54. Coverley D, Pelizon C, Trewick S, et al. Chromatin-bound Cdc6 persists in S and G2 phases in human cells, while soluble Cdc6 is destroyed in a cyclin A-cdk2 dependent process. J Cell Sci 2000;113:1929-38.
55. Robles L, Frost A, Davila M, et al. Down-regulation of Cdc6, a cell cycle regulatory gene, in prostate cancer. J Biol Chem 2002;277:25431-8.
56. Vaziri C, Saxena S, Jeon Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 2003;4:997-1008.